Listed

Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2016

Filed with the SEC on Aug 8, 2016 and accepted by EDGAR at Aug 8, 2016, 16:51 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-04-01 to 2016-06-30$1.8mus-gaap:Revenues
Revenue6 months2016-01-01 to 2016-06-30$2.4mus-gaap:Revenues
Cost of revenue3 months2016-04-01 to 2016-06-30$1.7mus-gaap:CostOfRevenue
Cost of revenue6 months2016-01-01 to 2016-06-30$2.2mus-gaap:CostOfRevenue
Gross profit3 months2016-04-01 to 2016-06-30$94.0kus-gaap:GrossProfit
Gross profit6 months2016-01-01 to 2016-06-30$250.0kus-gaap:GrossProfit
Research and development3 months2016-04-01 to 2016-06-30$10.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2016-01-01 to 2016-06-30$17.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2016-04-01 to 2016-06-30$2.2mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2016-01-01 to 2016-06-30$4.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-04-01 to 2016-06-30−$9.9mus-gaap:OperatingIncomeLoss
Operating income6 months2016-01-01 to 2016-06-30−$17.8mus-gaap:OperatingIncomeLoss
Net income3 months2016-04-01 to 2016-06-30−$10.9mus-gaap:NetIncomeLoss
Net income6 months2016-01-01 to 2016-06-30−$19.5mus-gaap:NetIncomeLoss
Operating cash flow6 months2016-01-01 to 2016-06-30−$21.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2016-01-01 to 2016-06-30$575.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-06-30$54.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-06-30$67.6mus-gaap:AssetsCurrent
Total assetsAt period end2016-06-30$78.9mus-gaap:Assets
Current liabilitiesAt period end2016-06-30$11.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-06-30$86.8mus-gaap:Liabilities
Shareholders' equityAt period end2016-06-30−$8.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-16-117287. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.